Literature DB >> 22521353

Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites.

Thomas Sersté1, Thierry Gustot, Pierre-Emmanuel Rautou, Claire Francoz, Hassane Njimi, Francois Durand, Dominique Valla, Didier Lebrec, Richard Moreau.   

Abstract

BACKGROUND & AIMS: The MELDNa score was developed to improve the prognostic value of the MELD score in cirrhosis and was built for serum sodium concentrations numerically capped between 125 and 140 mmol/L. This model is not validated in a well-defined population of patients with cirrhosis and refractory ascites in whom severe hyponatremia (≤ 125 mmol/L) is frequent. This study assessed the prognostic value of severe hyponatremia and the MELDNa score in these patients.
METHODS: A consecutive, single-centre, observational, prospective study was performed in patients with cirrhosis and refractory ascites defined according to the International Ascites Club criteria. The prevalence of low serum sodium was assessed in this population. Predictive factors of mortality were analyzed and compared.
RESULTS: One hundred seventy-four patients were included. Sixty-six (37.9%) had low serum sodium (< 130 mmol/L). Sixty-one (35.1%) had diuretic-intractable ascites due to severe hyponatremia (≤ 125 mmol/L). The median MELDNa score was 23 (10-33). The 1-year cumulative incidence of death was 55% (95% CI: 55-56%). The best predictive factors of mortality were the following: severe hyponatremia (≤ 125 mmol/L) as an underlying cause of refractory ascites, a higher Child-Pugh score, beta-blocker therapy, and a high frequency of large-volume paracentesis. The Child-Pugh score had a higher area under receiver operating curve to predict mortality than MELDNa.
CONCLUSIONS: In patients with cirrhosis and refractory ascites, severe hyponatremia and Child-Pugh score are better predictors of mortality than MELDNa.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22521353     DOI: 10.1016/j.jhep.2012.03.018

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  20 in total

1.  Management of hyponatremia in clinical hepatology practice.

Authors:  Paul Y Kwo
Journal:  Curr Gastroenterol Rep       Date:  2014

Review 2.  Approach to Hyponatremia in Cirrhosis.

Authors:  Bashar Attar
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-04-30

Review 3.  Electrolyte and Acid-Base Disturbances in End-Stage Liver Disease: A Physiopathological Approach.

Authors:  José Víctor Jiménez; Diego Luis Carrillo-Pérez; Rodrigo Rosado-Canto; Ignacio García-Juárez; Aldo Torre; David Kershenobich; Eduardo Carrillo-Maravilla
Journal:  Dig Dis Sci       Date:  2017-05-13       Impact factor: 3.199

Review 4.  Model for End-stage Liver Disease.

Authors:  Ashwani K Singal; Patrick S Kamath
Journal:  J Clin Exp Hepatol       Date:  2012-12-01

Review 5.  Hyponatremia in patients with liver diseases: not just a cirrhosis-induced hemodynamic compromise.

Authors:  G Liamis; T D Filippatos; A Liontos; M S Elisaf
Journal:  Hepatol Int       Date:  2016-06-21       Impact factor: 6.047

6.  Procalcitonin, and cytokines document a dynamic inflammatory state in non-infected cirrhotic patients with ascites.

Authors:  Bashar M Attar; Christopher M Moore; Magdalena George; Nicolae Ion-Nedelcu; Rafael Turbay; Annamma Zachariah; Guiliano Ramadori; Jawed Fareed; David H Van Thiel
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

7.  Circulating Elastin Fragments Are Not Affected by Hepatic, Renal and Hemodynamic Changes, But Reflect Survival in Cirrhosis with TIPS.

Authors:  M J Nielsen; J Lehmann; D J Leeming; R Schierwagen; S Klein; C Jansen; C P Strassburg; F Bendtsen; S Møller; T Sauerbruch; M A Karsdal; A Krag; J Trebicka
Journal:  Dig Dis Sci       Date:  2015-07-03       Impact factor: 3.199

8.  Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites.

Authors:  Yasunari Hiramine; Hirofumi Uto; Seiichi Mawatari; Shuji Kanmura; Yasushi Imamura; Takuya Hiwaki; Akiko Saishoji; Manei Oku; Koichi Tokushige; Shigeho Maenohara; Akio Ido
Journal:  J Gastroenterol       Date:  2020-09-21       Impact factor: 7.527

9.  Predictors of Mortality in Long-Term Follow-Up of Patients with Terminal Alcoholic Cirrhosis: Is It Time to Accept Remodeled Scores?

Authors:  Mirjana M Radisavljevic; Goran B Bjelakovic; Aleksandar V Nagorni; Miroslav P Stojanovic; Milan D Radojkovicn; Jasna Z Jovic; Aleksandra M Ignjatovic; Misa M Radisavljevic; Maja M Simonovic
Journal:  Med Princ Pract       Date:  2016-09-27       Impact factor: 1.927

Review 10.  Approach and management of dysnatremias in cirrhosis.

Authors:  Mauro Bernardi; Giacomo Zaccherini
Journal:  Hepatol Int       Date:  2018-09-10       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.